Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer

This trial is testing whether adding thalidomide to a combination of cetuximab and standard chemotherapy improves outcomes for people with a specific type of advanced colorectal cancer (left-sided, stage IV, that cannot be surgically removed). **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with stage IV colorectal cancer on the left side that cannot be removed with surgery - Your tumor has been tested and is RAS and BRAF wild-type (specific genetic characteristics) - You have not had chemotherapy before for this cancer - You have not previously received cetuximab treatment - Your liver, kidney, and bone marrow are functioning adequately - You are in reasonably good physical health (able to carry out daily activities) - Your expected survival is more than 3 months **You may NOT be eligible if...** - You have serious heart, liver, or kidney problems - You have another active cancer - You are pregnant or breastfeeding - You have an active infection - You have a known history of serious drug allergies - You are currently enrolled in another clinical trial Talk to your doctor to see if this trial is right for you.